Free "LabXchange" science education accelerator launched by Amgen Foundation and Harvard's Faculty of Arts and Sciences

AmgenThe Amgen Foundation and the Faculty of Arts and Sciences at Harvard University (Harvard FAS) today announced the global launch of LabXchangeâ„¢, a free online science education platform that provides users with access to personalized instruction, virtual lab experiences and networking opportunities across the global scientific community. LabXchange is purpose-built to drive more inclusion in the scientific process and spark collaboration to build creative, team-based approaches to real-world problems.

"Too many high school and college students lack the opportunity to directly explore the scientific process - where you build a hypothesis, understand a method, and determine how to apply it to an appropriate experimental problem," said Robert Lue, Ph.D., principal investigator of LabXchange and professor of the Practice of Molecular and Cellular Biology at Harvard. "For many students, science can feel like a collection of facts to memorize - which is contrary to what the scientific process is - it's a journey that requires bold thinking and deep imagination. With LabXchange, more students can come together and experience the joy of discovery."

Featuring virtual lab experiments developed at LabXchange along with other world-class assets created by validated partners, LabXchange brings the scientific process to life. By simulating key techniques in molecular and cellular biology, like using CRISPR to correct genetic defects, students can explore a wide range of scientific methods and build their acumen in harnessing science to solve real-life problems.

"Everyone needs science, and science needs everyone," said Robert A. Bradway, chairman and chief executive officer at Amgen. "At a time of remarkable scientific progress, we're excited by the potential of LabXchange to educate and inspire both students and lifelong learners of all ages."

LabXchange is designed to level the playing field for students and to promote science literacy for all. Key features of LabXchange include:

  • Free access to a library of world-class educational content including videos, interactive simulations and assessments.
  • Ability to mix and match materials, empowering teachers to create flexible learning pathways for classes or individual students that complement existing science curriculums.
  • Global networking functionality, enabling teachers to collaborate beyond a single classroom, school or district.

LabXchange builds upon other Amgen Foundation programs that support science education, such as the Amgen Biotech Experience and Amgen Scholars that are also at Harvard FAS and institutions around the world. To date, the Foundation has contributed more than $150 million to advancing science education programming globally as part of its mission to facilitate global collaboration on the United Nations Sustainable Development Goals (SDGs), notably SDG #4 on Quality Education, but also SDG #3 on Good Health and Well-Being.

For more information, please visit www.LabXchange.org.

About the Amgen Foundation

The Amgen Foundation seeks to advance excellence in science education to inspire the next generation of innovators, and invest in strengthening communities where Amgen staff members live and work. To date, the Foundation has donated over $300 million to local, regional, and international non-profit organizations that impact society in inspiring and innovative ways. The Amgen Foundation brings the excitement of discovery to the scientists of tomorrow through several signature programs, including Amgen Scholars and the Amgen Biotech Experience.

About Amgen

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

Most Popular Now

Novartis research shows technology talent increasi…

Novartis revealed the healthcare and pharma industry has emerged as a desired career destination for tech talent during the COVID-19 pandemic, in the Powerful Pairing res...

GSK COVID-19 vaccine development collaboration wit…

GSK's scientific collaboration with Clover Pharmaceuticals to develop an adjuvanted COVID-19 vaccine has entered into human clinical trials. Clover announced the initiati...

Lilly begins world's first study of a potential CO…

Eli Lilly and Company (NYSE: LLY) announced patients have been dosed in the world's first study of a potential antibody treatment designed to fight COVID-19. This inve...

Sanofi invests to make France its world class cent…

Sanofi detailed plans on how the Company will make significant investments in France to increase its vaccines research and production capacities, and contribute in respon...

Low-cost dexamethasone reduces death by up to one …

In March 2020, the RECOVERY (Randomised Evaluation of COVid-19 thERapY) trial was established as a randomised clinical trial to test a range of potential treatments for C...

Super-potent human antibodies protect against COVI…

A team led by Scripps Research has discovered antibodies in the blood of recovered COVID-19 patients that provide powerful protection against SARS-CoV-2, the coronavirus ...

Sanofi and Translate Bio expand collaboration to d…

Sanofi Pasteur, the vaccines global business unit of Sanofi, and Translate Bio (NASDAQ: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company, have agreed to ...

AstraZeneca to supply Europe with up to 400 millio…

AstraZeneca has reached an agreement with Europe's Inclusive Vaccines Alliance (IVA), spearheaded by Germany, France, Italy and the Netherlands, to supply up to 400 milli...

Gilead announces results from Phase 3 Trial of rem…

Gilead Sciences, Inc. (Nasdaq: GILD) announced topline results from the Phase 3 SIMPLE trial in hospitalized patients with moderate COVID-19 pneumonia. This open-label st...

Up to 45 percent of SARS-CoV-2 infections may be a…

An extraordinary percentage of people infected by the virus behind the ongoing deadly COVID-19 pandemic never show symptoms of the disease, according to the results of a ...

Bayer supports "The Challenge Initiative…

Today Bayer announced the support of "The Challenge Initiative" ("TCI" hereafter) with a payment of 10 million USD. Hosted at the Johns Hopkins Bloomberg School of Public...

Researchers identify potent antibody cocktail to t…

Researchers at the University of Maryland School of Medicine (UMSOM) evaluated several human antibodies to determine the most potent combination to be mixed in a cocktail...